Boceprevir
- Generic Name
- Boceprevir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H45N5O5
- CAS Number
- 394730-60-0
- Unique Ingredient Identifier
- 89BT58KELH
- Background
Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of...
- Indication
Boceprevir, when used in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b is indicated for use in the treatment of chronic HCV genotype 1 infection in adults .
- Associated Conditions
- Chronic Hepatitis C Genotype 1
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 58
- Registration Number
- NCT01756079
A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)
- Conditions
- Interventions
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- Liver Institute of Virginia
- Target Recruit Count
- 20
- Registration Number
- NCT01731301
- Locations
- 🇺🇸
Liver Institute of Virginia, Richmond, Virginia, United States
HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin
- Conditions
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Anna Cruceta
- Target Recruit Count
- 128
- Registration Number
- NCT01718301
- Locations
- 🇪🇸
Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
Boceprevir and Ucalm (St John&Apos;s Wort)
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- St Stephens Aids Trust
- Target Recruit Count
- 17
- Registration Number
- NCT01663922
- Locations
- 🇬🇧
St Stephen's AIDS Trust, London, United Kingdom
Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT01657552
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection
- Conditions
- Interventions
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Theodor Bilharz Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT01653236
- Locations
- 🇪🇬
Theodor Bilharz Research Institute, Giza, Egypt
Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)
- Conditions
- Interventions
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT01641666
A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 165
- Registration Number
- NCT01591460
Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)
- Conditions
- Interventions
- First Posted Date
- 2012-05-02
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT01590225
Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2015-09-21
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 11
- Registration Number
- NCT01585584
- Locations
- 🇨🇦
University of Calgary Liver Unit, Calgary, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.